Signal active
Bio
Eric joined NanoDimension in 2008 and was the first employee of NanoDimension’s Silicon Valley office. He is involved in deal sourcing, due diligence and deal structuring and focuses on NanoDimension’s life sciences investments together with Carl Pabo and Colin Walsh. He is a board member of Emulate and a board observer of Twist Bioscience, IonPath and Click Diagnostics. In addition to his investment and board roles at NanoDimension, Eric serves on the Commercialization Advisory Council for the Oregon Nanoscience and Microtechnologies Institute (ONAMI).
Previously, Eric was a consultant at Bain & Company in Zurich and San Francisco. While at Bain, Eric worked on strategy cases in healthcare, industrial goods and telecommunications and on the turn-around of an electrical component manufacturer. In addition, Eric spent eight months in Bain’s Private Equity Group.
Eric has an MS.c. from the London School of Economics and a BS/BA from the University of Florida.
Location
San Francisco, California, United States, North America
Social
Primary Organization
2002
57
20
12
11-50
Financial Services, Venture Capital, Nanotechnology
Jobs history
2
Partillion Bioscience
Board Member
Invalid date - Current
Visby Medical
Board Member
Invalid date - Current
Board and Advisor Roles
0
N/A
Invest in regions
Profile Resume
Eric Moessinger is the Partner at +ND Capital, based in United States, North America. With a background in Financial Services, Eric Moessinger has a rich history of leadership and innovation. Eric Moessinger studied BS unknown @ University of Central Florida. Explore their detailed professional journey, key connections, and contributions to the industry on our platform.
Recommendation from your interest
N/A
Investment portfolio
1
0
Personal investment
0
There is no personal investment available on this profile
Partner investment
16
Annouced Date | Organization Name | Funding Round | Investor Name | Money Raised |
---|---|---|---|---|
Dec 19, 2018 | - | Series C - Inscripta | +ND Capital | 30.0M |
Apr 04, 2019 | - | Series C - Inscripta | +ND Capital | 20.0M |
May 18, 2020 | SQZ Biotech | Series D - SQZ Biotech | +ND Capital | 65.0M |
Sep 26, 2023 | Partillion Bioscience | Seed Round - Partillion Bioscience | +ND Capital | 5.0M |
Exits
0
There is no exit available on this Profile
Invest in industries
Recent Activity
There is no recent news or activity for this profile.